G
Geneos Therapeutics
Developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment
About Geneos Therapeutics
Geneos Therapeutics is a biotechnology company focused on developing personalized cancer immunotherapies. The company operates in the biotechnology and pharmaceutical market, serving clients such as research institutions, hospitals, and pharmaceutical companies. Geneos's core product is the GT EPICTM platform, which is designed to enhance the efficiency and effectiveness of clinical trials globally. This platform leverages advanced technologies to create personalized neoantigen-targeting vaccines, aiming to improve patient outcomes in oncology. The business model revolves around partnerships, licensing agreements, and direct sales of their proprietary technologies. Revenue is generated through these collaborations, clinical trial services, and the commercialization of their immunotherapy products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 74.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2023 | $5M | $85M | SHC Shanghai Biomedical Fund | ↗ |
| SERIES A✓Equity / VC | Apr 2023 | $5M | $85M | 3B Future Health Fund | ↗ |
Growth signals
Latest recorded traffic for Geneos Therapeutics is 1.8K monthly website visits, up 102.2% over the last three months. Geneos Therapeutics's team grew 9.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Geneos Therapeutics in the Whitemarsh Township ecosystem
The Geneos Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Sante Ventures
Inovio Pharmaceuticals
Korea Investment Partners
Flerie Invest
Global Bio Fund
Ted Fjällman
3B Future Health Fund
SHC Shanghai Biomedical Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Geneos Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Geneos Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










